Overview of oral modified-release opioid products for the management of chronic pain

Annals of Pharmacotherapy

Volumn 40, Issue 7-8, 2006, Pages 1327-1335

  Amabile, Celene M ^a   Bowman, Bill J ^b  

^a Gaston Memorial Hospital   (United States)

^b MIDWESTERN UNIVERSITY   (United States)

Author keywords

Hydromorphone; Morphine; Opioid; Oxycodone

Indexed keywords

ANALGESIC AGENT; CODEINE; DEXTROPROPOXYPHENE; FENTANYL; HYDROMORPHONE; METHADONE; MORPHINE; MORPHINE SULFATE; OPIATE; OXYCODONE; PETHIDINE;

CHRONIC PAIN; CLINICAL PRACTICE; CONCENTRATION RESPONSE; CONFUSION; CONSTIPATION; DOSE RESPONSE; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HEALTH CARE ORGANIZATION; HEALTH PRACTITIONER; HUMAN; NAUSEA; PATIENT COMPLIANCE; PEER REVIEW; PRIORITY JOURNAL; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; STANDARD; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DRUG HYPERSENSITIVITY; HUMANS; PAIN;

EID: 33746989258     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G259     Document Type: Review

References (33)

1. Vallerand AH. The use of long-acting opioids in chronic pain management. Nurs Clin North Am 2003;38:435-45.
2. Gourlay GK. Sustained relief of chronic pain: pharmacokinetics of sustained release morphine. Clin Pharmacokinet 1998;35:173-90.
3. Reder RF. Opioid formulations: tailoring to the needs in chronic pain. Eur J Pain 2001;5(suppl A):109-11.
4. Simpson BB, Ogorzaly MC. Medicinal plants. In: Prancan KM, Barter PW, Luhrs M, eds. Economic botany. 2nd ed. New York: McGraw-Hill, 1995:376-406.
5. Evans WC. Alkaloids. In: Evans WC, ed. Trease and Evans' pharmacognosy. 14th ed. London: WB Saunders, 1999:340-408.
6. Hanson GR. Analgesic, antipyretic, and anti-inflammatory drugs. In: Gennaro AR, ed. Remington: the science and practice of pharmacy. 20th ed. Baltimore, MD: Lippincott Williams & Wilkins, 2000:1444-63.
7. Gutstein HB, Akil H. Opioid analgesics. In: Hardman JG, Limbard LE, eds. Goodman & Gillman's the pharmacologic basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001:569-620.
8. Brase D, Dewey WL. Pain control with narcotic analgesics. In: Wingard LB, Brody TM, Larner J, Schwartz A, eds. Human pharmacology: molecular to clinical. St. Louis, MO: Mosby-Year Book, 1991:383-99.
9. Jackson KC, Lipman AG. Opioid analgesics. In: Lipman AG, ed. Pain management for primary care clinicians. Bethesda, MD: American Society of Health-System Pharmacists, 2004:71-90.
10. Ripamonti C, Bianchi M. The use of methadone for cancer pain. Hematol Oncol Clin North Am 2002;16:543-55.
11. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook. 12th ed. Hudson, OH: Lexi-Comp, 2004.
12. Package insert. OxyContin (oxycodone). Stamford, CT: Purdue Pharma LP., February 2004.
13. Package insert. Avinza (morphine sulfate). San Diego: Ligand Pharmaceuticals, February 2003.
14. Package insert. Palladone (hydromorphone). Stamford, CT: Purdue Pharma L.P., November 2004.
15. Principles of analgesic use in the treatment of acute pain and chronic pain. 5th ed. Glenview, IL: American Pain Society, 2003.
16. Paddock R, Beer EG, Bellville JW, Cliberti BJ, Forest WH Jr, Miller EV. Analgesic and side effects of pentazocine and morphine in a large population of postoperative patients. Clin Pharmacol Ther 1969;10:355-65.
17. Package insert. Kadian (morphine sulfate). Piscataway, NJ: Alpharma Branded Products Division, November 2004.
18. Package insert. Oramorph (morphine sulfate). Columbus, OH: Roxane Laboratories, May 2001.
19. Package insert. MS Contin (morphine sulfate). Stamford, CT: Purdue Fredrick, December 2004.
20. Wilkinson K. Cancer treatments. Clin J Oncol Nurs 2003;7:458-60.
21. Leslie S. The Contin delivery system: dosing considerations. J Allergy Clin Immunol 1986;78:768-73.
22. Boroda C, Miller RB, Leslie ST, Nicol EG, Thomson I. Comparison of the bioavailability of aminophylline in a conventional base and in a continuous-release base. J Clin Pharmacol 1973;13:383-7.
23. Kaplin M, Miliman A, Kaplan L, Collins M. Comparative clinical efficacy and abuse potential of oral long acting opioids in a chronic pain outpatient center (abstract 868). American Pain Society Annual Meeting, Vancouver, BC, Canada, 2004.
24. Purdue Pharma L.P. suspends marketing of Palladone capsules. Purdue Pharma press release. www.pharma.com/pressroom/news/20050713-01. pdf (accessed 2005 July 21).
25. Hydromorphone hydrochloride extended-release capsules: alcohol-Palladone interaction. FDA alert for healthcare professionals. www.fda.gov/cder/drug/ InfoSheets/HCP/hydromorphoneHCP.pdf (accessed 2005 July 21).
26. ALZA announces 2000 first quarter financial results. ALZA press release. www.alza.com/alza/pr_966278856 (accessed 2005 Jul 20).
27. Penwest announces that Endo reports receiving final FDA approval for oxymorphone ER. PR Newswire. www.prnewswire.com/cgi-bin/stories. pl?ACCT=109&STORY=/www/story/06-23-2006/0004385962& EDATE=(accessed 2006 Jun 27).
28. Bogner RH, Szwejkowski J, Houston A. Release of morphine sulfate from compounded slow-release capsules: the effect of formulation on release. IJPC 2001;5:401-5.
29. Webster KD, Al-Achi A, Greenwood R. In vitro studies on the release of morphine sulfate from compounded slow-release morphine-sulfate capsules. IJPC 1999;3:409-11.
30. Glowiak DL, Green JL, Bowman BJ. In vitro evaluation of extemporaneously compounded "slow release" capsules containing morphine sulfate or oxycodone hydrochloride. IJPC 2005;9:157-64.
31. Cherny NI, Portenoy RK. Practical issues in the management of cancer pain. In: Wall PD, Melzack R, eds. Textbook of pain. 4th ed. London: Churchill Livingstone, 1999:1479-523.
32. Broomhead A, Kerr R, Tester W, et al. Comparison of a once-a-day sustained release morphine formulation with standard oral morphine. J Pain Symptom Manage 1997;14:63-73.
33. Portenoy RK, Sciberras A, Eliot L, Loewen G. Butler J, Devane J. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage 2002;23:292-300.